An observational study in Prostate Cancer, sponsored by Ipsen. Not yet recruiting. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Ipsen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Prostatic Neoplasms by Ipsen — 1 open to participants now, 1 under way, none of them phase 3. Prostatic Neoplasms · Ipsen.
Among the 27 studies in Prostatic Neoplasms by Ipsen, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2026, is one of 11 observational ones, and was the 27th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →1 of the 27 studies in Prostatic Neoplasms by Ipsen is open now.
Of the 1,234 Prostatic Neoplasms studies recruiting now, 932 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 7 · Phase 4 2
First in 2006; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 819 is above the median of 200 across 1,311 observational studies indexed under Prostatic Neoplasms.
Median enrollment 106 across the 16 interventional studies, 510 across the 11 observational. Of the 26 that completed or were terminated, 12 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ipsen is the lead sponsor of 291 studies on the registry; 19 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 27 studies in Prostatic Neoplasms by Ipsen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prostate cancer and its treatment, particularly androgen deprivation therapy (ADT) may affect different aspects of a person's quality of life, including physical well-being and daily activities.
The purpose of this study is to evaluate baseline factors that stabilize or improve quality of life in patients with prostate cancer who are initiating triptorelin treatment as ADT, in routine clinical practice.
Participants in this study will be patients with prostate cancer whose treating physician has decided to initiate treatment with triptorelin.
This is an observational study. No treatment will be assigned as part of the study, and all medical decisions will be made by the treating physician according to routine clinical practice.
Participants will be followed for approximately 6 months. Information collected during the study may include demographics and medical characteristics, prostate cancer and treatments characteristics, physical activity, supportive care and quality of life. Questionnaires about quality of life and physical activity will be completed by participants at the start of the study and again approximately 6 months later. Information on adverse events occurring during the study will also be collected.
Adult males with prostate cancer initiating triptorelin treatment in routine clinical practice and meeting the study eligibility criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients are eligible to be included in the study only if all the following criteria apply:
Exclusion Criteria
Patients will not be included in the study if they meet any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Identification of baseline factors including: demographic, clinical, disease and treatment factors, associated with stabilization (change:]-10; 10[) or improvement (change ≥10) of Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score
Time frame: At 6 months
Participants' baseline demographic characteristics
Including: * Age. * Partnership status. * Employment status. * Area of residence. * Socioeconomic status.
Time frame: At baseline
Participants' clinical characteristics at baseline
Including: * BMI * Eastern Cooperative Oncology Group (ECOG) Performance status score. * G8 score if applicable. * Comorbidity status, medical and surgical history, and systemic treatments for comorbidities. * Participant's level of physical activity, using IPAQ questionnaire.
Time frame: At baseline
Prostate cancer characteristics at diagnosis and baseline
Including: * Prostate Cancer (PCa) presentation (new diagnosis or recurrence/progression) at baseline. * Gleason score/International Society of Urological Pathology (ISUP) group * TNM (Tumor Node Metastasis) at diagnosis. * Prostate Specific Antigen (PSA) and testosterone levels at PCa diagnosis. * Previous treatments received for PCa, if any.
Time frame: At baseline
Participants symptoms at baseline
Time frame: At baseline
Participants' PCa treatment patterns at baseline
* Triptorelin treatment modalities * Radiotherapy modalities * Associated systemic PCa treatments
Time frame: At baseline
Participants' healthcare pathway/supportive care done or planned
Including: * Pretreatment assessments * Visits to supportive health care professionals done or planned. * Participation in a dedicated healthcare pathway (as a one-day hospital stay with visits to several healthcare professionals). * Associated prescriptions or recommendations * Complementary information on cancer patient organizations and/or websites.
Time frame: At baseline
Evolution of PCa at 6-month follow-up according to investigator's opinion
Evolution of PCa at 6-month follow-up according to investigator's opinion: control / stable / progression.
Time frame: At 6 months
Symptoms and biological characteristics at 6 months
Time frame: At 6 months
Participant's level of physical activity, using International Physical Activity Questionnaire (IPAQ) questionnaire
The International Physical Activity Questionnaire (IPAQ) is a participant-reported questionnaire used to assess physical activity level. Higher scores indicate higher levels of physical activity.
Time frame: At 6 months
Participants' Quality Of life (QoL)
* FACT-P total score, sub-scores and individual items, at baseline and at 6- month follow-up, and their changes from baseline. * European Organisation for Research and Treatment of CancerQuality-of-Life Questionnaire Prostate Module (EORTC QLQ-PR25) sexual activity individual items and domain scores at baseline and at 6-month follow-up and changes from baseline.
Time frame: At baseline and at 6 months
Participants' PCa treatment patterns at 6 months
* Collection of triptorelin administrations from initiation * Radiotherapy modalities in case of changes, * Associated systemic PCa treatments in case of changes.
Time frame: At baseline and at 6 months
Participants' healthcare pathway/supportive care at 6 months
• Participant's healthcare pathway/type of supportive care in case of changes.
Time frame: At 6 months
Identification of factors associated with participant's quality of life
• Identification of baseline factors, including demographic, clinical, disease and treatment factors, associated with stabilization (change: \]-3;3\[) or improvement (change ≥3) of Physical Well-Being (PWB) and Prostate Cancer Specific (PCS) sub-scores of FACT-P at 6 months after inclusion, using a logistic model.
Time frame: At 6 months
Percentage of participants with adverse events
An adverse event (AE) is any untoward medical occurrence in a participant. The percentage of participants experiencing at least one adverse event, including cardiovascular events occurring after initiation of triptorelin treatment, will be assessed during study follow-up.
Time frame: From enrollment to Month 6
No study locations are listed for this record.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Data sharing details ↗ · www.ipsen.com
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Feb 2028, 15 months later.
Of 109 industry-sponsored observational studies under Prostatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 65. This study's planned 15 months is below that.
Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 29 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.